![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Tuesday, September 14, 2021 1:10:40 PM
https://endpts.com/how-jan-skvarka-and-trillium-talked-their-way-into-biotechs-hottest-vax-summer/
How Jan Skvarka and Trillium went from down and out to buyout with Pfizer
Jason Mast
Editor
How do you pull off one of the most lucrative biotech turnarounds in history?
You begin, it seems, by calling up the chief business officer of a Big Pharma sitting beneath a $30 billion-plus windfall and asking if he might want to get in on a modest investment in an up-and-coming company.
John DeYoung
At least that’s what Trillium CEO Jan Skvarka asked Pfizer global business vice president John DeYoung in early summer 2021. Trillium was valued at a couple of shades under $1 billion at the time, an astronomical valuation from the penny stock mire it sat at when Skvarka arrived in October 2019.
But they could still use some cash, so Skvarka asked DeYoung if Pfizer, which had already invested $25 million, would chip in another 25. It was less than a thousandth of their Covid-19 vaccine revenue, barely half of what a star athlete like Kansas City Chiefs quarterback Patrick Mahomes made in a season.
By Aug. 21, Pfizer had agreed to buy out all of Trillium for $2.3 billion, or roughly what it would cost to buy the Kansas City Chiefs.
It was a rapid close for a company with an almost unprecedentedly rapid rise. The valuation surpassed even the estimates the company’s own financial advisors, Clearwater, provided. It was more than triple Trillium’s closing price-per-share and more than 200 times the value of the company when Skvarka arrived.
For all that value creation, the Slovakian ex-investor and financial advisor will earn a Mahomesian sum, taking home just over $25 million from his Trillium stock options, according to SEC filings Monday.
How much credit Skvarka deserves for the turnaround remains an open question. Unlike Pharmacyclics and other previous biotech cinderellas, Trillium does not owe its turnaround to any disease-changing data or molecules nearing approval.
On the contrary, even some of their results from earlier this year have been a mixed bag.
Instead, Trillium began trading up in the winter of 2020 for well, no clear reason. The company had to actually put out a statement that February just to make clear it didn’t know of any undisclosed info that could account for its surging stock.
Soon, though, Trillium would rise for a different, clearer reason: the broader interest in CD47, a target many executives hoped could expand and turbocharge the reach of immunotherapies — and one that Trillium had been working on since at least 2013. That March, Gilead bought out Irv Weissman’s Forty Seven for $4.9 billion, and Trillium’s stock jumped from $4 to $7 amid speculation that they too might be bought out.
The speculation, it turned out, was accurate. According to the new documents, Trillium was already exploring a partnership with a company. It hired Centerview two days after Gilead announced its buyout.
That June, after Trillium released promising but not overwhelming data for its CD47 antibody, executives began their first talks with Pfizer. The first $25 million investment came in September 2020, days after AbbVie bet $200 million on I-Mab’s CD47 antibody.
The only data it released between that investment and the buyout were met with mixed reviews.
At the same time, though, Skvarka, a veteran of Bain and PureTech, made key decisions on the path to the acquisition. He all but ended development on Trillium’s main preclinical molecule and slowed development on one of their CD47 antibodies, while accelerating another.
And when he reached out to Pfizer over the summer, he told them he wouldn’t settle for a price-per-share below $13 — a gutsy ask, given Trillium’s stock would fall to as little as half that in those months.
Deborah Baron
But Pfizer was game. After only a couple of exchanges DeYoung and Deborah Baron, Pfizer’s SVP of business development, called Skvarka to say they wanted to buy out Trillium for $15 per share, or roughly $1.8 billion. And they said they wanted to close by Aug. 23.
After that, only two other companies were involved, as Trillium tried to gauge the industry’s broader interest — one biopharma that never showed much inclination and another that eventually decided Trillium was too early stage. Trillium’s board didn’t even bother reaching out to the first company executives had spoken to in 2020, deciding it didn’t have the capabilities to pull off such a bid.
After a few back and forth negotiations, Pfizer and Trillium agreed to a $2.3 billion buyout — $18.50 per share — on Aug. 21. They announced the deal two days later, precisely on the New York pharma’s schedule.
Recent AMRN News
- Latest Research Highlighting VASCEPA®/VAZKEPA® (icosapent ethyl) REDUCE-IT® Subgroup Data and New Mechanistic Insights into Eicosapentaenoic Acid (EPA) to be Presented at European Society of Cardiology (ESC) Congress • GlobeNewswire Inc. • 08/22/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/05/2024 09:30:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/01/2024 08:54:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/01/2024 08:54:46 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/31/2024 11:05:34 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 07/31/2024 11:05:26 AM
- Amarin Reports Second Quarter 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 07/31/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/29/2024 09:30:08 PM
- Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Portugal • GlobeNewswire Inc. • 07/17/2024 08:15:00 PM
- Amarin to Report Second Quarter 2024 Financial Results and Host Conference Call on July 31, 2024 • GlobeNewswire Inc. • 07/17/2024 12:00:00 PM
- Amarin Partner EddingPharm Receives Regulatory Approval for VASCEPA® (Icosapent Ethyl) in Mainland China for Cardiovascular Risk Reduction (CVRR) • GlobeNewswire Inc. • 07/08/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 11:30:10 AM
- Amarin Board of Directors Announces CEO Transition • GlobeNewswire Inc. • 06/04/2024 11:30:00 AM
- Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A. • GlobeNewswire Inc. • 05/28/2024 12:15:23 PM
- Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference • GlobeNewswire Inc. • 05/06/2024 12:00:00 PM
- Amarin Reports First Quarter 2024 Business Update and Financial Results • GlobeNewswire Inc. • 05/01/2024 11:00:00 AM
- Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event • GlobeNewswire Inc. • 04/24/2024 06:00:01 PM
- Amarin Announces Results of Annual General Meeting of Shareholders • GlobeNewswire Inc. • 04/22/2024 12:00:25 PM
- Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024 • GlobeNewswire Inc. • 04/15/2024 12:00:00 PM
- Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24 • GlobeNewswire Inc. • 04/08/2024 12:00:00 PM
- New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • PR Newswire (Canada) • 04/08/2024 10:30:00 AM
- New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • GlobeNewswire Inc. • 04/06/2024 07:30:00 PM
- Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe • GlobeNewswire Inc. • 04/03/2024 12:00:00 PM
- Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo • GlobeNewswire Inc. • 03/25/2024 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 03/04/2024 10:30:53 PM
FEATURED Mawson Finland Limited Expands Known Mineralized Zones at Rajapalot: New Lens Intercepts 21.75 m at 5.25 g/t Gold & 515 ppm Cobalt • Sep 4, 2024 9:02 AM
FEATURED Integrated Ventures Acquires 51% Stake In GetTrim.Com (TM), Telemedicine Platform With Focus On Expansion Into Booming GLP-1 Powered Weight Loss Market • Sep 4, 2024 8:45 AM
VAYK Confirms Receiving Revenue from First Airbnb Property with 1.4 Million Annual Revenue Goal • VAYK • Sep 4, 2024 9:34 AM
Avant Technologies Announces Strategic Review Process Intended to Maximize Shareholder Value • AVAI • Sep 4, 2024 8:00 AM
PickleJar Launches National "Get on the Bus" Campaign, Unveils Thompson Square Tour Bus Wrap • PKLE • Sep 4, 2024 7:17 AM
Maybacks Global and Inventel Products To Launch Global 24 Hour Shopping Channel • AHRO • Sep 3, 2024 9:15 AM